



HAL
open science

[Letter to editor] Altered microRNA expression in severe COVID-19: Potential prognostic and pathophysiological role

Nathalie Garnier, Kato Pollet, Marie Fourcot, Morgan Caplan, Guillemette Marot, Julien Goutay, Julien Labreuche, F. Soncin, Rabah Boukherroub, Didier Hober, et al.

► **To cite this version:**

Nathalie Garnier, Kato Pollet, Marie Fourcot, Morgan Caplan, Guillemette Marot, et al.. [Letter to editor] Altered microRNA expression in severe COVID-19: Potential prognostic and pathophysiological role. *Clinical and Translational Medicine*, 2022, 12 (6), pp.e899. 10.1002/ctm2.899 . hal-03700328

HAL Id: hal-03700328

<https://hal.science/hal-03700328>

Submitted on 27 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

LETTER TO EDITOR

Altered microRNA expression in severe COVID-19: Potential prognostic and pathophysiological role

Dear Editor,

The pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is beginning to be elucidated but the role of microRNAs (miRNAs), small non-coding RNAs that regulate gene expression, remains incompletely understood. In order to shed light on the role of miRNAs in the pathophysiology of SARS-CoV-2 infection, we have analyzed microRNA (miRNA) expression in nasopharyngeal swabs of coronavirus disease 2019 (COVID-19) patients. We found that miRNA expression was globally reduced in severe COVID-19 and identified several miRNAs of interest to discriminate severe and non-severe COVID-19. Our results suggest that these miRNAs are involved in the pathophysiology of COVID-19 and represent not only promising biomarkers but also possible targets for antiviral or anti-inflammatory treatment strategies.

miRNA expression was measured in nasopharyngeal swab specimens from patients with severe, non-severe COVID-19 and controls (Table S1). The number of expressed miRNAs was lower in the severe (median: 151) compared to the other groups (medians non-severe: 184; controls: 190.5) (Figure 1A). Univariate analyses revealed that 14 miRNAs were differentially expressed in severe COVID-19 versus controls (Table 1) and five of these, namely hsa-miR-125a-5p, hsa-miR-200b-3p, hsa-miR-340-5p, hsa-miR-455-5p and hsa-miR-491-5p, were also down-regulated in the severe versus the non-severe COVID-19 groups (Figure 1B, panels a,b; Table 1). A paralleled down-regulation of miRNA expression in severe COVID-19 was reported lately.¹ RNA silencing pathways have been identified as antiviral defense mechanisms in plants and insects, and possibly in mammalian cells.² To escape this antiviral defense, plant and insect viruses possess virus-encoded suppressors of RNA interference, and this may extend to mammalian cells.³ An interesting hypothesis to explain our findings is thus that SARS-CoV-2 targets cellular miRNA biogenesis. In line with this, expression of the RNA interference machinery components Ago2, Dicer

and Drosha was significantly down-regulated in COVID-19 patients.⁴ Furthermore, miRNA depletion enhances proinflammatory cytokine production, including expression of interleukin-6 (IL-6).⁵ The global repression of miRNA expression in severe COVID-19 that we observed here may thus be causally linked to the hyperinflammatory state found in severe COVID-19.

Multivariate sparse Partial Least Squares-Discriminant Analysis (sPLS-DA) analysis selected eight miRNAs, hsa-miR-125a-5p, hsa-miR-1290, hsa-miR-15b-5p, hsa-miR-491-5p, hsa-miR-532-3p, hsa-miR-200b-3p, hsa-miR-629-5p and hsa-miR-103a-2-5p, that discriminated severe and the non-severe COVID-19 (Figure 1B, panels b,c). Five of these miRNAs were not differentially expressed in univariate analyses (Figure 1B, panel c) but were necessary to build scores with linear discriminant analysis. When using leave-one-out cross validation, 35 out of 41 patients (85.37%) were correctly predicted (Table S2), suggesting that these miRNAs could be used in scores to cluster patients. The coefficients of these scores should be built from a future study that includes more patients and validated in an independent cohort.

The comparison of results of differential expression analysis and sPLS-DA revealed three miRNA in common, namely hsa-miR-125a-5p, hsa-miR-491-5p and hsa-miR-200b-3p (Figure 1B, panel b). These miRNAs discriminated severe from non-severe cases with areas under the curve ranging from 0.76 to 0.79 (Figure 2). To evaluate their performance as biomarkers to predict disease severity, it would be interesting to determine their expression at different time points, that is, before, during and after resolution of severe COVID-19.

We hypothesized that the 10 miRNAs selected by sPLS-DA and/or differential analysis (Figure 1B) play a role in the pathophysiology of severe COVID-19. Ninety-five validated target genes were retrieved (Table S3). Gene ontology (GO) enrichment analysis revealed enrichment for five, eight and zero GO terms associated with biological process, molecular function and cellular component, respectively

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Clinical and Translational Medicine* published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.




FIGURE 1 miRNA expression in non-severe compared to severe COVID-19. (A) Number of miRNAs detected in nasopharyngeal swab specimens of severe ($n = 20$), non-severe COVID-19 ($n = 21$) and controls ($n = 20$). Box plots showing median and interquartile ranges of the number of expressed miRNAs in each group. (B) Box-plots showing the expression of miRNAs that are differentially expressed between severe (S) and non-severe (NS) COVID-19 and control groups (Ctrl) in univariate analyses (panels Ba,b). Box-plots showing the expression of miRNAs that discriminate severe and non-severe COVID-19 by the sPLS-DA multivariate analysis (panels Bb,c). The miRNAs identified by both analyses are shown in panel Bb. The bars show the medians and the boxes the interquartile ranges of normalized miRNA expression. (C) Severe (S, triangles) and non-severe COVID-19 cases (NS, circles) are discriminated by miRNA expression by sPLS-DA analysis

(Tables S4 and S5). Enriched biological processes were involved in deoxyribonucleid acid (DNA) damage, ubiquitination and antigen processing and presentation (Table S4). Enriched molecular functions were involved in protein kinase activity, ubiquitination and RNA polymerase II activity (Table S5). Kegg pathway analysis revealed enrichment in pathways that play a role in ubiquitination,

viral infections and the immune response (Table 2). Reactome pathway analysis showed enrichment for pathways involved in antigen processing, NFkappaB and other signaling pathways (Table 2).

Of the miRNAs found of interest to discriminate between severe and non-severe COVID-19 in our study, some were reported to be implicated in viral and other

TABLE 1 miRNAs differentially expressed between severe COVID-19 and controls and non-severe COVID-19

miRNA	Log ₂ fold-change severe COVID-19 versus control	Adjusted p-value	Log ₂ fold-change severe COVID-19 versus non-severe COVID-19	Adjusted p-value
hsa-miR-125a-5p	-5.170	.044	-4.853	.045
hsa-miR-200b-3p	-3.012	.044	-2.752	.013
hsa-miR-200c-3p	-2.328	.044	-1.280	NS
hsa-miR-218-5p	-6.534	.044	-5.165	NS
hsa-miR-27a-3p	-2.848	.044	-1.790	NS
hsa-miR-30c-5p	-8.041	.044	-7.232	NS
hsa-miR-30d-5p	-3.327	.044	-1.717	NS
hsa-miR-375	-1.977	.044	-0.859	NS
hsa-miR-378a-3p	-4.365	<.001	-1.919	NS
hsa-miR-422a	-5.682	.002	0.067	NS
hsa-miR-455-5p	-2.724	.044	-2.260	.034
hsa-miR-532-5p	-1.898	.044	-0.499	NS
hsa-miR-340-5p	-5.601	.044	-4.744	.011
hsa-miR-491-5p	-4.887	.044	-4.326	.031

Abbreviation: NS, not significant.


**FIGURE 2** Receiver operator characteristic (ROC) analysis for the discrimination of severe and non-severe COVID-19. ROC curve and area under the ROC curve (AUC) values for the classification into severe and non-severe COVID-19 based on miRNA expression are shown for the three miRNAs identified in common by sPLS-DA and univariate analysis

TABLE 2 Kegg and reactome pathways enrichment analysis

Kegg pathway	p-Value	Adjusted p-value (BH*)
hsa04120_ubiquitin_mediated_proteolysis	.001	.004
hsa05162_measles	.001	.004
hsa05169_Epstein-Barr_virus_infection	.001	.004
hsa05170_human_immunodeficiency_virus_1_infection	.002	.004
hsa04218_cellular_senescence	.002	.004
hsa04630_JAK-STAT_signaling_pathway	.003	.004
hsa05166_human_T-cell_leukemia_virus_1_infection	.008	.012
hsa05131_shigellosis	.011	.014
hsa05200_pathways_in_cancer	.032	.035
Reactome pathway	p-Value	Adjusted p-value (BH*)
R-HSA-983168_antigen_processing:ubiquitination_and_proteasome_degradation	<.001	<.001
R-HSA-2871837_FCERI_mediated_NF-kB_activation	<.001	<.001
R-HSA-5607764_CLEC7A(Dectin-1)_signaling	<.001	<.001
R-HSA-9020702_interleukin-1_signaling	<.001	<.001
R-HSA-202424_downstream_TCR_signaling	<.001	<.001

*BH: Benjamini-Hochberg false discovery rate correction

infections: miR-455-5p was up-regulated in rabies virus infection in vitro, decreased suppressor of cytokine signaling 3 (SOCS3) expression and increased signal transducer and activator of transcription 3 (STAT3) activity, resulting in enhanced viral replication and the production of IL-6.⁶ Furthermore, this miRNA targeted the C-C motif chemokine receptor 5 (CCR5).⁷ Of interest, CCR5 is involved in severe COVID-19 and has been proposed as anti-inflammatory treatment target.⁸ Taken together, this underlines the role of hsa-miR-455-5p in viral infections and the inflammatory response and its potential as target of therapeutic interventions.

hsa-miR-532-3p diminished the levels of ASK1 and downstream phosphorylation/translocation of p38 MAPK during lipopolysaccharide (LPS)/ tumor necrosis factor- α (TNF- α)-induced inflammation in macrophages and reduced the release of various pro-inflammatory cytokines and chemokines, including IL-6 and TNF-alpha.⁹ IL-6 is a proinflammatory cytokine that has been reported to be involved in the cytokine storm observed in severe COVID-19.¹⁰ The down-regulation of anti-inflammatory miRNAs, such as hsa-miR-532-3p, hsa-miR-340-5p and hsa-miR-455-5p, in severe COVID-19 (Table 1) is in line with a hyper-inflammatory state in severe COVID-19. Supplementation of these anti-inflammatory miRNAs may represent a novel therapeutic strategy.

Recently, direct and indirect miRNA interactions with other miRNAs have been described (reviewed¹¹). Therefore, it cannot be excluded that the miRNAs identified in this study directly or indirectly influence expression of

other miRNAs and thus have a broad impact on miRNA and gene expression.

We next searched for miRNAs that may directly target the SARS-CoV-2 genome among the miRNAs associated with severe COVID-19. We found that hsa-miR-15b-5p was predicted to bind to the SARS-CoV-2 genome at 16 positions (Table S6). Furthermore, hsa-miR-15b-5p was confirmed to interact with SARS-CoV-2 RNA in vitro.¹² hsa-miR-15b-5p was down-regulated in severe COVID-19 in our study (Figure 1B, panel c) and in the lungs of hamsters infected with SARS-CoV-2.¹³ Taken together, this suggests that the down-regulation of hsa-miR-15b-5p may represent a mechanism of SARS-CoV-2 to escape the host antiviral defense.

In conclusion, our analysis of miRNA expression in nasopharyngeal swabs revealed a general reduction of miRNA expression in severe COVID-19 patients. Several miRNAs of interest to discriminate severe and non-severe COVID-19 were identified. Functional analysis of these miRNAs suggested a role in the pathophysiology of the disease. Further characterization of their implication in SARS-CoV-2 infection will enable elucidation of the molecular mechanisms and may reveal potential targets for antiviral or anti-inflammatory treatment of COVID-19.

ACKNOWLEDGEMENTS

The authors thank B. Guerred, S. Menasria and S. Miloudi for excellent technical assistance. They acknowledge the work of technicians and engineers of the Biology and Pathology Center of the Lille University Hospital (CHU

Lille) who are involved in the diagnostics of SARS-CoV-2. This research was supported by I-SITE ULNE, the Centre Hospitalier Universitaire de Lille and Université de Lille.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

Nathalie Garnier^{1,#}

Kato Pollet^{1,2,#}

Marie Fourcot³

Morgan Caplan⁴

Guillemette Marot⁵

Julien Goutay⁴

Julien Labreuche⁶

Fabrice Soncin^{7,8}

Rabah Boukherroub²

Didier Hober¹

Lille COVID Research Network (LICORNE)

Sabine Szunerits²

Julien Poissy^{4,9}

Ilka Engelmann¹ 

¹Univ Lille, CHU Lille, Laboratoire de Virologie ULR3610, Lille, France

²Univ Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520 - IEMN, Lille, France

³Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France

⁴CHU de Lille, Pôle de réanimation, Lille, France

⁵Univ Lille, CHU Lille, ULR 2694 – METRICS, Lille, France

⁶Department of Biostatistics, CHU Lille, Lille, France

⁷CNRS/IIS/Centre Oscar Lambret/Lille University SMMiL-E Project, CNRS Délégation Hauts-de-France, Lille, France

⁸Laboratory for Integrated Micro Mechatronic Systems, Institute of Industrial Science, University of Tokyo, CNRS IRL2820, Tokyo, Japan

⁹CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, Inserm U1285, Univ Lille, CHU Lille, Lille, France

Correspondence

Ilka Engelmann, Univ Lille, CHU Lille, Laboratoire de Virologie ULR3610, Lille 59000, France.

Email: ilka.engelmann@chru-lille.fr

Study group members: Lille COVID Research Network (LICORNE)

Lille University Hospital/Centre Hospitalier Universitaire Lille: Comed: LAMBERT Marc; YELNIK Cécile; POKEERBUX Ryad; ANDRE Loïc; BAKHACHE Ed-gar; SCHERPEREEL Arnaud; DESBORDES Jacques; BAUTIN Nathalie; FRY Stéphanie; DUTHOIT Louise; DUHAMEL

Nicolas; De GROOTE Pascal; PUISIEUX François; GAXATTE Cédric; BEUSCART Jean-Baptiste; CHARPENTIER Anne; Emergency Department: GOLDSTEIN Patrick; FACON Alain; VANHEEMS FRANCOIS; CUNY Jerome; JOLY Roch; WIEL Eric; CHARBONNIER DINNER Leslie; PEGORARO Vincent; Surgical Critical Care, Department of Anesthesiology and Critical Care: KIPNIS Eric; BOYER-BESSEYRE Marielle; BOULO Marie; BIGNON Anne; BORTOLOTTI Perrine; FAJARDY Marion; Post-operative Intensive Care, Department of Anesthesiology and Critical Care: LEBUFFE Gilles; FACKEURE Remi; CARPENTIER Laurent; ANDRIEU Gregoire; CAPRON Benoit; ONIMUS Jerome; SANDERS Virginie; JEAN-NETEAU Antoine; AMROUN Djihad; Réanimation SALENGRO, Intensive Care Department: BODDAERT Pauline; CAPLAN Morgan; COUSIN Nicolas; DUBURCQ Thibault; DURAND Arthur; EL KALIOUBIE Ahmed; FAVORY Raphael; GIRARDIE Patrick; GOUTAY Julien; HOUARD Marion; JAILLETTE Emmanuelle; JOURDAIN Mercedes; LEDOUX Goeffrey; MATHIEU Daniel; MOREAU Anne-Sophie; NIGEON Olivier; NILES Christopher; NSEIR Saad; ONIMUS Thierry; PARMENTIER Erika; POISSY Julien; PREAU Sébastien; ROBRIQUET Laurent; Dr ROUZE Anahita; Dr SIMONNET Arthur; Dr SIX Sophie; Dr TOUSSAINT Aurélie; Surgical Emergency Department, Department of Anesthesiology and Critical Care: GARRIGUE Delphine; LALLE-MANT Florence; ROHN Aurelien; HENRY Lois; BIJOK Benjamin; STRECKER Guillaume; JOSE-FOWICZ; TAVERNIER Benoit; JOSEFOWICZ Elsa; DEVAUCHELLE Pauline; Cardiothoracic Anesthesia and Intensive Care, Department of Anesthesiology and Critical Care: ROBIN Emmanuel; DECOENE Christophe; AIT OUARAB Slimane; MOUSSA Mouhammed; JOULIN Olivier; LEROY Guillaume; GANTOIS Guillaume; BRANDT Caroline; SADDOK Noredine; DUPRE Celine; LEROY Xavier; MARIE Raphael; LIU Vincent; FOULON Valentin; MASSIAS Sylvain; RYTTER Nicolas; DEBLAUWE Delphine; PETTIGAND Vincent; MULLER Christophe; DES-BORDES Jacques; DUSSON Catherine; Centre de Biologie Pathologie: BROUSSEAU Thierry; Hémostase—Inserm U1011-EGID: SUSEN Sophie; RAUCH Antoine; LASSALLE Fanny; DUPONT Annabelle; MCU CORSEAUX Delphine; JEANPIERRE Emmanuelle; BAUTERS Anne; TRILLOT Nathalie; Immunologie—Inserm 1286: LABALETTE Myriam; LEFEVRE Guillaume; DEMARET Julie; VARLET Pauline; BOU SALEH Mohamed; Virologie—ULR3610: BOCKET Laurence; ALIDJINO Enagnon Kazali; PREVOST Brigitte; LAZREK Mouna; TINEZ Claire; MILLIERE Laurine, BOUAROURO Youssef, ENGELMANN Ilka; HOBBER Didier; Institut de

Microbiologie: SENDID Boualem; Hématologie: NIBOUREL Olivier; Hémostase/Pole BPG: TOURNOY Antoine; Anatomopathologie: COPIN Marie-Christine; DUBOIS Romain; GIBIER Jean-Baptiste; GNEMMI Viviane; HUMEZ Sarah; KADRI Malik; LETEURTRE Emmanuelle; PERBET Romain; Centre de Ressources Biologiques/DRI: DEPLANQUE Dominique; Service de maladies infectieuses et tropicales: DOZIER Aurélie; ASSAF Ady; CHOPIN Marie-charlotte; FAURE Emmanuel; VUOTTO Fanny; PANAGET Sophie; FAURE Karine; LEROY Clara; PRASIVORAVONG Julie; BERTHON Céline; GOURSAUD Laure; PROVOT François; LENCI Hélène; BERVAR Jean-François; PREVOTAT Anne

#Nathalie Garnier and Kato Pollet contributed equally to this study.

ORCID

Ilka Engelmänn  <https://orcid.org/0000-0001-7489-3786>

REFERENCES

1. Wilson JC, Kealy D, James SR, et al. Integrated miRNA/cytokine/chemokine profiling reveals severity-associated step changes and principal correlates of fatality in COVID-19. *iScience*. 2022;25:103672. <https://doi.org/10.1016/j.isci.2021.103672>
2. Takahashi T, Heaton SM, Parrish NF. Mammalian antiviral systems directed by small RNA. *PLoS Pathog*. 2021;17:e1010091. <https://doi.org/10.1371/journal.ppat.1010091>
3. Libri V, Miesen P, van Rij RP, Buck AH. Regulation of microRNA biogenesis and turnover by animals and their viruses. *Cell Mol Life Sci*. 2013;70:3525-3544. <https://doi.org/10.1007/s00018-012-1257-1>
4. Mousavi SR, Sajjadi MS, Khosravian F, et al. Dysregulation of RNA interference components in COVID-19 patients. *BMC Res Notes*. 2021;14:401. <https://doi.org/10.1186/s13104-021-05816-0>
5. Aguado LC, Schmid S, Sachs D, et al. microRNA function is limited to cytokine control in the acute response to virus infection. *Cell Host Microbe*. 2015;18:714-722. <https://doi.org/10.1016/j.chom.2015.11.003>
6. Tu Z, Xu M, Zhang J, et al. Pentagalloylglucose inhibits the replication of rabies virus via mediation of the miR-455/SOCS3/STAT3/IL-6 pathway. *J Virol*. 2019;93:e00539-19. <https://doi.org/10.1128/JVI.00539-19>
7. Xing Q, Xie H, Zhu B, et al. MiR-455-5p suppresses the progression of prostate cancer by targeting CCR5. *BioMed Res Int*. 2019;2019:e6394784. <https://doi.org/10.1155/2019/6394784>
8. Patterson BK, Seethamraju H, Dhody K, et al. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. *Int J Infect Dis*. 2021;103:25-32. <https://doi.org/10.1016/j.ijid.2020.10.101>
9. Dinesh P, Kalaiselvan S, Sujitha S, Rasool M. MicroRNA-532-3p regulates pro-inflammatory human THP-1 macrophages by targeting ASK1/p38 MAPK pathway. *Inflammation*. 2021;44:229-242. <https://doi.org/10.1007/s10753-020-01325-7>
10. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. *Rev Medi Virol*. 2020;30:e2141. <https://doi.org/10.1002/rmv.2141>
11. Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. *Dis Model Mech*. 2021;14:dmm047662. <https://doi.org/10.1242/dmm.047662>
12. Siniscalchi C, Di Palo A, Russo A, Potenza N. Human MicroRNAs interacting with SARS-CoV-2 RNA sequences: computational analysis and experimental target validation. *Front Genet*. 2021;12:678994. <https://doi.org/10.3389/fgene.2021.678994>
13. Kim WR, Park EG, Kang K-W, et al. Expression analyses of MicroRNAs in hamster lung tissues infected by SARS-CoV-2. *Mol Cells*. 2020;43:953-963. <https://doi.org/10.14348/molcells.2020.0177>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.